Teleflex lands FDA win for Arrow UltraQuik needles

January 25, 2013 by MassDevice staff

Medical device company Teleflex touts 510(k) clearance for its Arrow UltraQuik peripheral nerve block needles.

Teleflex logo

Limerick, Pa.-based Teleflex (NYSE:TFX) won FDA clearance for the latest in its line of peripheral nerve block needles, the Arrow UltraQuik.

The Arrow UltraQuik joins Teleflex's StimuQuik and StimuQuik Echo, devices aimed at helping physicians perform nerve blocking, whether with ultrasound alone, via nerve stimulation, or through a combined approach, according to a press release.

Sign up to get our free newsletters delivered right to your inbox.

The medical products giant earlier this month signed a 3-year contract with group purchasing organization Premier to provide hand-held laparoscopic surgical instruments.

TFX shares were fairly flat today, gaining 0.1% to trade at $74.79 as of about 1:25 p.m.